Amy J. Osborne

Amy J. Osborne

Auto-generated profile, based on publicly available information

Amy J. Osborne

Department of Pediatric Nephrology, Bristol Renal and Royal Bristol Children Hospital, University of Bristol, Bristol, United Kingdom

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AOAmy J. Osborne
Amy J. Osborne
MBMatteo Breno
Matteo Breno
NBNicolo Ghiringhelli Borsa
Nicolo Ghiringhelli Borsa
FBFengxiao Bu
Fengxiao Bu
VFVéronique Frémeaux-Bacchi
Véronique Frémeaux-Bacchi
SPStephen Perkins
Stephen Perkins
Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are associated with dysregulation and overactivation of the complement alternative pathway. Typically, gene analysis for aHUS and C3G is undertaken in small patient numbers, yet it is unclear which genes most frequently predispose to aHUS or C3G. Accordingly, we performed a six-center analysis of 610 rare genetic variants in 13 mostly complement genes (CFH, CFI, CD46, C3, CFB, CFHR1, CFHR3, CFHR4, CFHR5, CFP, PLG, DGKE, and THBD) from >3500 patients with aHUS and C3G. We report 371 novel rare variants (RVs) for aHUS and 82 for C3G. Our new interactive Database of Complement Gene Variants was used to extract allele frequency data for these 13 genes using the Exome Aggregation Consortium server as the reference genome. For aHUS, significantly more protein-altering rare variation was found in five genes CFH, CFI, CD46, C3, and DGKE than in the Exome Aggregation Consortium (allele frequency < 0.01%), thus correlating these with aHUS. For C3G, an association was only found for RVs in C3 and the N-terminal C3b-binding or C-terminal nonsurface-associated regions of CFH. In conclusion, the RV analyses showed nonrandom distributions over the affected proteins, and different distributions were observed between aHUS and C3G that clarify their phenotypes.

1 October 2014 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
ERElizabeth Rodriguez
Elizabeth Rodriguez
PRPavithra M. Rallapalli
Pavithra M. Rallapalli
AOAmy J. Osborne
Amy J. Osborne
SPStephen Perkins
Stephen Perkins
AHUS (atypical haemolytic uraemic syndrome), AMD (age-related macular degeneration) and other diseases are associated with defective AP (alternative pathway) regulation. CFH (complement factor H), CFI (complement factor I), MCP (membrane cofactor protein) and C3 exhibited the most disease-associated genetic alterations in the AP. Our interactive structural database for these was updated with a total of 324 genetic alterations. A consensus structure for the SCR (short complement regulator) domain showed that the majority (37%) of SCR mutations occurred at its hypervariable loop and its four conserved Cys residues. Mapping 113 missense mutations onto the CFH structure showed that over half occurred in the C-terminal domains SCR-15 to -20. In particular, SCR-20 with the highest total of affected residues is associated with binding to C3d and heparin-like oligosaccharides. No clustering of 49 missense mutations in CFI was seen. In MCP, SCR-3 was the most affected by 23 missense mutations. In C3, the neighbouring thioester and MG (macroglobulin) domains exhibited most of 47 missense mutations. The mutations in the regulators CFH, CFI and MCP involve loss-of-function, whereas those for C3 involve gain-of-function. This combined update emphasizes the importance of the complement AP in inflammatory disease, clarifies the functionally important regions in these proteins, and will facilitate diagnosis and therapy.

1 October 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
BWBenjamin Wooden
Benjamin Wooden
ABAndrew Beenken
Andrew Beenken
EMElena Martinelli
Elena Martinelli
KSKen Saida
Ken Saida
AKAndrea L. Knob
Andrea L. Knob
SSSimone Sanna-Cherchi
Simone Sanna-Cherchi
Key Points: We conducted a clinical, genetic, and pathological analysis on 64 cases from 39 families with TRPC6-associated podocytopathy (TRPC6-AP). Analysis of 37,542 individuals excluded a major contribution of loss-of-function variants to TRPC6-AP, legitimating current drug discovery approaches. This study identifies key features of disease that can help intervention studies design and suggests similarities between TRPC6-AP and primary FSGS. Background: Understanding the genetic basis of human diseases has become integral to drug development and precision medicine. Recent advancements have enabled the identification of molecular pathways driving diseases, leading to targeted treatment strategies. The increasing investment in rare diseases by the biotech industry underscores the importance of genetic evidence in drug discovery and approval processes. Here we studied a monogenic Mendelian kidney disease, TRPC6-associated podocytopathy (TRPC6-AP), to present its natural history, genetic spectrum, and clinicopathological associations in a large cohort of patients with causal variants in TRPC6 to help define the specific features of disease and further facilitate drug development and clinical trials design. Methods: The study involved 64 individuals from 39 families with TRPC6 causal missense variants. Clinical data, including age of onset, laboratory results, response to treatment, kidney biopsy findings, and genetic information, were collected from multiple centers nationally and internationally. Exome or targeted sequencing was performed, and variant classification was based on strict criteria. Structural and functional analyses of TRPC6 variants were conducted to understand their effect on protein function. In-depth reanalysis of light and electron microscopy specimens for nine available kidney biopsies was conducted to identify pathological features and correlates of TRPC6-AP. Results: Large-scale sequencing data did not support causality for TRPC6 protein-truncating variants. We identified 21 unique TRPC6 missense variants, clustering in three distinct regions of the protein, and with different effects on TRPC6 3D protein structure. Kidney biopsy analysis revealed FSGS patterns of injury in most cases, along with distinctive podocyte features including diffuse foot process effacement and swollen cell bodies. Most patients presented in adolescence or early adulthood but with ample variation (average 22, SD ±14 years), with frequent progression to kidney failure but with variability in time between presentation and kidney failure. Conclusions: This study provides insights into the genetic spectrum, clinicopathological associations, and natural history of TRPC6-AP. Clinical Trial registry name and registration number: A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis, NCT05213624.

1 November 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AOAmy J. Osborne
Amy J. Osborne
RNRuodan Nan
Ruodan Nan
AMAmi Miller
Ami Miller
JBJayesh S. Bhatt
Jayesh S. Bhatt
JGJayesh Gor
Jayesh Gor
SPStephen Perkins
Stephen Perkins
Factor H (FH) is the major regulator of C3b in the alternative pathway of the complement system in immunity. FH comprises 20 short complement regulator (SCR) domains, including eight glycans, and its Y402H polymorphism predisposes those who carry it to age-related macular degeneration. To better understand FH complement binding and self-association, we have studied the solution structures of both the His-402 and Tyr-402 FH allotypes. Analytical ultracentrifugation revealed that up to 12% of both FH allotypes self-associate, and this was confirmed by small-angle X-ray scattering (SAXS), MS, and surface plasmon resonance analyses. SAXS showed that monomeric FH has a radius of gyration (Rg) of 7.2–7.8 nm and a length of 25 nm. Starting from known structures for the SCR domains and glycans, the SAXS data were fitted using Monte Carlo methods to determine atomistic structures of monomeric FH. The analysis of 29,715 physically realistic but randomized FH conformations resulted in 100 similar best-fit FH structures for each allotype. Two distinct molecular structures resulted that showed either an extended N-terminal domain arrangement with a folded-back C terminus or an extended C terminus and a folded-back N terminus. These two structures are the most accurate to date for glycosylated full-length FH. To clarify FH functional roles in host protection, crystal structures for the FH complexes with C3b and C3dg revealed that the extended N-terminal conformation accounted for C3b fluid-phase regulation, the extended C-terminal conformation accounted for C3d binding, and both conformations accounted for bivalent FH binding to glycosaminoglycans on the target cell surface.

9 March 2024 in npj Systems Biology and Applications
Verified
Journal Article
Open access
PDF file
AOAmy J. Osborne
Amy J. Osborne
ABAgnieszka Bierzynska
Agnieszka Bierzynska
ECElizabeth Colby
Elizabeth Colby
UAUwe Andag
Uwe Andag
PKPhilip A. Kalra
Philip A. Kalra
CCColin Campbell
Colin Campbell
Chronic kidney diseases (CKD) have genetic associations with kidney function. Univariate genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) associated with estimated glomerular filtration rate (eGFR) and blood urea nitrogen (BUN), two complementary kidney function markers. However, it is unknown whether additional SNPs for kidney function can be identified by multivariate statistical analysis. To address this, we applied canonical correlation analysis (CCA), a multivariate method, to two individual-level CKD genotype datasets, and metaCCA to two published GWAS summary statistics datasets. We identified SNPs previously associated with kidney function by published univariate GWASs with high replication rates, validating the metaCCA method. We then extended discovery and identified previously unreported lead SNPs for both kidney function markers, jointly. These showed expression quantitative trait loci (eQTL) colocalisation with genes having significant differential expression between CKD and healthy individuals. Several of these identified lead missense SNPs were predicted to have a functional impact, including in SLC14A2. We also identified previously unreported lead SNPs that showed significant correlation with both kidney function markers, jointly, in the European ancestry CKDGen, National Unified Renal Translational Research Enterprise (NURTuRE)-CKD and Salford Kidney Study (SKS) datasets. Of these, rs3094060 colocalised with FLOT1 gene expression and was significantly more common in CKD cases in both NURTURE-CKD and SKS, than in the general population. Overall, by using multivariate analysis by CCA, we identified additional SNPs and genes for both kidney function and CKD, that can be prioritised for further CKD analyses.

3 November 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
AOAmy J. Osborne
Amy J. Osborne
SHSamantha Hayward
Samantha Hayward
ECElizabeth Colby
Elizabeth Colby
UAUwe Andag
Uwe Andag
PKPhilip A. Kalra
Philip A. Kalra
CCColin Campbell
Colin Campbell
In membranous nephropathy (MN), an autoimmune kidney condition, univariate genome-wide association studies (GWAS) have identified Human Leucocyte Antigen ( HLA ) and M-type phospholipase A2 receptor ( PLA2R1 ) genetic risk variants. Multivariate-single nucleotide polymorphism (SNP) canonical correlation analysis (CCA) with transcriptomics analysis, can uncover additional insights within this context. We applied CCA to our National Unified Renal Translational Research Enterprise (NURTuRE)- chronic kidney disease (CKD) and Salford Kidney Study (SKS) European datasets, identifying 1095 HLA and 46 PLA2R1 SNPs showing significant MN correlation, and single-cell gene enrichment. Top SNP combinations showed greater significance in both MN by multivariate-SNP CCA, and MN and diabetic nephropathy (Type 1) by allele frequency analysis compared to healthy and non-MN groups. ATF6B , C2, CYP21A2 , and HLA-DRB1 colocalised with top HLA SNPs and showed significant differential expression in MN (published immune transcriptomics datasets). HLA-DQB1, HLA-DRB5 and RNF5 showed significant differential expression with lead SNP genotype status in MN and CKD. These previously unreported SNP and gene results are candidates for MN and potentially Type 1 diabetic nephropathy risk prediction.